TrialBlood2021

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.

Johann Hitzler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.